Relay Begin Period Cash Flow from 2010 to 2025
| RLAY Stock | USD 2.86 0.10 3.38% |
Begin Period Cash Flow | First Reported 2019-03-31 | Previous Quarter 136.8 M | Current Value 154.5 M | Quarterly Volatility 141.2 M |
Check Relay Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relay Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 36.5 M, Interest Income of 36.5 M or Depreciation And Amortization of 4.3 M, as well as many indicators such as Price To Sales Ratio of 55.88, Dividend Yield of 0.0 or PTB Ratio of 0.94. Relay financial statements analysis is a perfect complement when working with Relay Therapeutics Valuation or Volatility modules.
Relay | Begin Period Cash Flow |
Latest Relay Therapeutics' Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Relay Therapeutics over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Relay Therapeutics' Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relay Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Relay Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 145,985,505 | |
| Geometric Mean | 111,410,695 | |
| Coefficient Of Variation | 87.74 | |
| Mean Deviation | 94,748,632 | |
| Median | 73,226,000 | |
| Standard Deviation | 128,086,933 | |
| Sample Variance | 16406.3T | |
| Range | 405.7M | |
| R-Value | 0.48 | |
| Mean Square Error | 13468.2T | |
| R-Squared | 0.23 | |
| Significance | 0.06 | |
| Slope | 13,008,984 | |
| Total Sum of Squares | 246093.9T |
Relay Begin Period Cash Flow History
About Relay Therapeutics Financial Statements
Relay Therapeutics investors use historical fundamental indicators, such as Relay Therapeutics' Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Relay Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 146.4 M | 179.5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.